NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.
NexImmune has raised $3.7M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.
NexImmune's investors include New Enterprise Associates, Pfizer Venture Investments, ArrowMark Partners, Irving Investors, Amgen Ventures.
NexImmune is headquartered in Gaithersburg, United States.
NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.
NexImmune is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NexImmune — Funding & Investors." VCBacked, February 2, 2024, https://www.vcbacked.co/company/neximmune. Accessed August 14, 2026.
VCBacked. (2024). NexImmune — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/neximmune
{{cite web |title=NexImmune — Funding & Investors |url=https://www.vcbacked.co/company/neximmune |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated